YHB Investment Advisors Inc. trimmed its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 14.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,936 shares of the biopharmaceutical company’s stock after selling 9,053 shares during the period. YHB Investment Advisors Inc.’s holdings in Bristol-Myers Squibb were worth $3,374,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Renaissance Technologies LLC raised its stake in shares of Bristol-Myers Squibb by 108.5% in the second quarter. Renaissance Technologies LLC now owns 13,488,200 shares of the biopharmaceutical company’s stock worth $751,563,000 after acquiring an additional 7,020,200 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of Bristol-Myers Squibb by 185.2% in the second quarter. Franklin Resources Inc. now owns 6,098,935 shares of the biopharmaceutical company’s stock worth $339,830,000 after acquiring an additional 3,960,191 shares during the last quarter. Jennison Associates LLC raised its stake in shares of Bristol-Myers Squibb by 16.2% in the third quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock worth $1,711,689,000 after acquiring an additional 3,735,453 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Bristol-Myers Squibb by 2,990.5% in the second quarter. Janus Henderson Group PLC now owns 3,634,128 shares of the biopharmaceutical company’s stock worth $202,494,000 after acquiring an additional 3,516,536 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in shares of Bristol-Myers Squibb by 42,071.5% in the second quarter. Arrowstreet Capital Limited Partnership now owns 3,331,549 shares of the biopharmaceutical company’s stock worth $185,634,000 after acquiring an additional 3,323,649 shares during the last quarter. Institutional investors own 69.80% of the company’s stock.
A number of equities analysts have weighed in on BMY shares. UBS Group reaffirmed a “buy” rating and issued a $72.00 target price (up from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. Vetr raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 price target for the company in a research note on Monday, October 9th. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Citigroup boosted their price target on shares of Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, October 18th. Finally, BMO Capital Markets set a $49.00 price objective on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a report on Thursday, October 12th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $65.38.
In other news, Director Theodore R. Samuels II purchased 4,000 shares of the company’s stock in a transaction on Friday, December 15th. The shares were purchased at an average cost of $62.30 per share, with a total value of $249,200.00. Following the completion of the transaction, the director now owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the sale, the executive vice president now directly owns 9,251 shares in the company, valued at $585,033.24. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.
Shares of Bristol-Myers Squibb Co (NYSE BMY) traded up $0.68 on Friday, reaching $63.48. 11,646,403 shares of the company traded hands, compared to its average volume of 6,440,000. Bristol-Myers Squibb Co has a fifty-two week low of $50.36 and a fifty-two week high of $66.10. The firm has a market capitalization of $103,900.00, a PE ratio of 24.99, a price-to-earnings-growth ratio of 2.17 and a beta of 1.08. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46.
The firm also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Investors of record on Friday, January 5th were issued a dividend of $0.40 per share. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Thursday, January 4th. This represents a $1.60 annualized dividend and a yield of 2.52%. Bristol-Myers Squibb’s dividend payout ratio is presently 62.99%.
WARNING: “YHB Investment Advisors Inc. Sells 9,053 Shares of Bristol-Myers Squibb Co (BMY)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/04/yhb-investment-advisors-inc-has-3-37-million-position-in-bristol-myers-squibb-co-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.